Results 241 to 250 of about 5,691,277 (301)

Perinatal, socioenvironmental, and neurological factors to predict motor delay in infants born preterm

Developmental Medicine &Child Neurology, EarlyView.
Abstract Aim To determine the best combination of perinatal characteristics, socioenvironmental factors, and neurological examination at term‐equivalent age for identifying motor delay at 3 months 2 weeks corrected age in infants born preterm between 29 weeks and 36 weeks of gestation.
Melanie Gagnon, Mathieu Dehaes, Mi‐Suk Kang Dufour, Marie‐Michèle Gagnon, Gabriel Côté‐Corriveau, Leanne Brabant, Sophie Tremblay, Thuy Mai Luu, Marie‐Noelle Simard   +8 more
wiley   +1 more source

The Colombian Medical Cannabis Paradox: A Scoping Review of Structural Barriers and Health Inequity. [PDF]

Int J Environ Res Public Health
Marín Arroyave OP, León Cruz P.
europepmc   +1 more source

Neuropsychiatric Outcomes Associated With GLP‐1 Receptor Agonist Use in Medicare Beneficiaries With Type 2 Diabetes: Variation by Treatment Pattern and Obesity Status

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Glucagon‐like peptide‐1 (GLP‐1) receptors are expressed in brain regions governing mood, reward and stress, yet the neuropsychiatric effects of GLP‐1 receptor agonist (GLP‐1 RA) therapy remain poorly characterized. We estimated associations between GLP‐1 RA use and neuropsychiatric disorders and variation by obesity status and treatment ...
Seo Hyon Baik, Fitsum Baye, Haotian Xian, Kin Wah Fung, Clement J. McDonald   +4 more
wiley   +1 more source

Medical cannabis legalization and the use of illicit drugs, alcohol, and tobacco. [PDF]

J Cannabis Res
Al Hallaj H, Barakat Z.
europepmc   +1 more source

UK Medical Cannabis Registry: An Analysis of Outcomes of Medical Cannabis Therapy for Hypermobility-Associated Chronic Pain. [PDF]

ACR Open Rheumatol
Dickinson M, Erridge S, Warner-Levy J, Clarke E, McLachlan K, Coomber R, Holden W, Rucker JJ, Platt MW, Sodergren MH.   +9 more
europepmc   +1 more source

Medical Cannabis Formulations, Administration Routes, and Dosing: Perspectives of Patients With Cancer Who Consume. [PDF]

Clin Ther
Nayak MM, Chai PR, Tung S, Revette A, Braun IM.   +4 more
europepmc   +1 more source

Medical cannabis authorization and opioid milligram equivalents over time in patients with chronic pain: a retrospective analysis. [PDF]

Pain Med
Sexton M, Glodosky NC, Cleveland M, Cuttler C, Lee E, Polston GR, Furnish T, Lerman I, Schuster NM, Wallace MS.   +9 more
europepmc   +1 more source

Post-legalization rise in German medical cannabis interest: evidence from Google trends as surrogate marker. [PDF]

J Cannabis Res
Kirchberger MC.
europepmc   +1 more source

Medical Cannabis for Best Supportive Care of Patients Affected by Cancers of the Head and Neck: A Narrative Review. [PDF]

In Vivo
Perri F, Marciano ML, Zotta A, Pontone M, Piccirillo A, Casale M, DI Filippo P, Sarno MR, D' Aniello R, Cascella M, Maiolino P.   +10 more
europepmc   +1 more source